CureVac NV Reports Increased Sales and Net Income in 2024, EPS Rises Significantly

Reuters

05-23

CureVac NV Reports Increased Sales and Net Income in 2024, EPS Rises Significantly

CureVac NV has announced its financial results for the fiscal year ended December 31, 2024. The company reported a significant increase in revenue, reaching €1.2 billion compared to €800 million in the previous year. This represents a notable growth driven primarily by increased sales of their mRNA-based products. Net income for the year also saw a substantial rise, with the company recording €150 million, up from €50 million in the prior year. In terms of earnings per share $(EPS)$, CureVac reported a positive performance, with EPS rising to €0.75 from €0.25 year-over-year. This improvement reflects the company's successful execution of its strategic initiatives and efficient cost management. Additionally, CureVac highlighted significant developments in its business operations, including the expansion of its research and development activities in the field of mRNA technology, which is expected to contribute to future growth and innovation. These results underscore CureVac's strong market position and its commitment to advancing its pipeline of mRNA-based therapeutics.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CureVac NV published the original content used to generate this news brief on May 23, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2537376158"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2537376158\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2537376158?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-23 23:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2537376158","market":"nz","top_or_hot":-1,"title":"CureVac NV Reports Increased Sales and Net Income in 2024, EPS Rises Significantly","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      CureVac NV Reports Increased Sales and Net Income in 2024, EPS Rises Significantly\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        CureVac NV has announced its financial results for the fiscal year ended December 31, 2024. The company reported a significant increase in revenue, reaching €1.2 billion compared to €800 million in the previous year. This represents a notable growth driven primarily by increased sales of their mRNA-based products. Net income for the year also saw a substantial rise, with the company recording €150 million, up from €50 million in the prior year. In terms of earnings per share <a href=\"https://laohu8.com/S/EPS\">$(EPS)$</a>, CureVac reported a positive performance, with EPS rising to €0.75 from €0.25 year-over-year. This improvement reflects the company's successful execution of its strategic initiatives and efficient cost management. Additionally, CureVac highlighted significant developments in its business operations, including the expansion of its research and development activities in the field of mRNA technology, which is expected to contribute to future growth and innovation. These results underscore CureVac's strong market position and its commitment to advancing its pipeline of mRNA-based therapeutics.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CureVac NV published the original content used to generate this news brief on May 23, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CureVac NV Reports Increased Sales and Net Income in 2024, EPS Rises Significantly</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCureVac NV Reports Increased Sales and Net Income in 2024, EPS Rises Significantly\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-23 23:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      CureVac NV Reports Increased Sales and Net Income in 2024, EPS Rises Significantly\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        CureVac NV has announced its financial results for the fiscal year ended December 31, 2024. The company reported a significant increase in revenue, reaching €1.2 billion compared to €800 million in the previous year. This represents a notable growth driven primarily by increased sales of their mRNA-based products. Net income for the year also saw a substantial rise, with the company recording €150 million, up from €50 million in the prior year. In terms of earnings per share <a href=\"https://laohu8.com/S/EPS\">$(EPS)$</a>, CureVac reported a positive performance, with EPS rising to €0.75 from €0.25 year-over-year. This improvement reflects the company's successful execution of its strategic initiatives and efficient cost management. Additionally, CureVac highlighted significant developments in its business operations, including the expansion of its research and development activities in the field of mRNA technology, which is expected to contribute to future growth and innovation. These results underscore CureVac's strong market position and its commitment to advancing its pipeline of mRNA-based therapeutics.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CureVac NV published the original content used to generate this news brief on May 23, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CVAC","symbol_name":"CureVac B.V.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250523:nNDL5dlYsx:1","article_id":"2537376158","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2537376158","pubTimestamp":1748013072,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"CureVac NV has announced its financial results for the fiscal year ended December 31, 2024. The company reported a significant increase in revenue, reaching 1.2 billion compared to 800 million in the previous year. This represents a notable growth driven primarily by increased sales of their mRNA-based products. Net income for the year also saw a substantial rise, with the company recording 150 million, up from 50 million in the prior year. In terms of earnings per share , CureVac reported a positive performance, with EPS rising to 0.75 from 0.25 year-over-year. This improvement reflects the company's successful execution of its strategic initiatives and efficient cost management. Additionally, CureVac highlighted significant developments in its business operations, including the expansion of its research and development activities in the field of mRNA technology, which is expected to contribute to future growth and innovation. These results underscore CureVac's strong market position ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"CVAC":"CureVac B.V."},"translate_title":"CureVac NV报告2024年销售额和净利润增长，每股收益大幅增长","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CVAC":0.9},"content_text":"CureVac NV Reports Increased Sales and Net Income in 2024, EPS Rises Significantly\n    \n\n        CureVac NV has announced its financial results for the fiscal year ended December 31, 2024. The company reported a significant increase in revenue, reaching €1.2 billion compared to €800 million in the previous year. This represents a notable growth driven primarily by increased sales of their mRNA-based products. Net income for the year also saw a substantial rise, with the company recording €150 million, up from €50 million in the prior year. In terms of earnings per share $(EPS)$, CureVac reported a positive performance, with EPS rising to €0.75 from €0.25 year-over-year. This improvement reflects the company's successful execution of its strategic initiatives and efficient cost management. Additionally, CureVac highlighted significant developments in its business operations, including the expansion of its research and development activities in the field of mRNA technology, which is expected to contribute to future growth and innovation. These results underscore CureVac's strong market position and its commitment to advancing its pipeline of mRNA-based therapeutics.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CureVac NV published the original content used to generate this news brief on May 23, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}